Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Update on PSMA PET/CT in Prostate Cancer and the Unmet Need for Imaging of RCC
October 16, 2025 | 3:30 p.m. ET
In this webinar, attendees will learn how advanced imaging with 68Gallium PSMA 11 enhances clinical decision-making in prostate cancer. Attendees will also examine diagnostic PET/CT in renal cancer utilizing 89Zr-girentuximab as evidenced by the ZIRCON study.
Jaideep Sohi, MD
Dr. Jaideep S. Sohi is a Johns Hopkins fellowship-trained PET CT specialist with over 5 years of experience. He currently serves as the president of American Molecular Imaging, and also serves as clinical faculty at Northwestern Department of Radiology.
Daniel D. Joyce, MD, MS
Dr. Daniel D. Joyce is at Urology Vanderbilt Nashville. He attended Mayo Medical School, completed his residency at Vanderbilt University Medical Center, and completed a fellowship at the Mayo Clinic in Rochester, Minnesota. His clinical interests are kidney cancer, testis cancer, bladder cancer, prostate cancer, and genitourinary cancer.
This is a non-CME, company-led program developed and sponsored by Telix Pharmaceuticals, intended for healthcare professionals only. The content of this company-directed program is not sponsored or endorsed by the American Urological Association (AUA).